- Home
- SRZN vs COYA Comparison
SRZN vs COYA Comparison
Compare SRZN & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- COYA
- Stock Information
- Founded
- SRZN 2015
- COYA 2020
- Country
- SRZN United States
- COYA United States
- Employees
- SRZN N/A
- COYA N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- COYA Health Care
- Exchange
- SRZN Nasdaq
- COYA Nasdaq
- Market Cap
- SRZN 120.0M
- COYA 107.0M
- IPO Year
- SRZN N/A
- COYA 2022
- Fundamental
- Price
- SRZN $13.06
- COYA $6.00
- Analyst Decision
- SRZN Strong Buy
- COYA Strong Buy
- Analyst Count
- SRZN 2
- COYA 5
- Target Price
- SRZN $38.50
- COYA $16.20
- AVG Volume (30 Days)
- SRZN 38.1K
- COYA 299.7K
- Earning Date
- SRZN 11-07-2025
- COYA 11-06-2025
- Dividend Yield
- SRZN N/A
- COYA N/A
- EPS Growth
- SRZN N/A
- COYA N/A
- EPS
- SRZN N/A
- COYA N/A
- Revenue
- SRZN $12,621,000.00
- COYA $423,452.00
- Revenue This Year
- SRZN N/A
- COYA $40.80
- Revenue Next Year
- SRZN N/A
- COYA N/A
- P/E Ratio
- SRZN N/A
- COYA N/A
- Revenue Growth
- SRZN N/A
- COYA N/A
- 52 Week Low
- SRZN $5.90
- COYA $4.65
- 52 Week High
- SRZN $18.17
- COYA $8.29
- Technical
- Relative Strength Index (RSI)
- SRZN 45.71
- COYA 45.68
- Support Level
- SRZN $13.42
- COYA $6.07
- Resistance Level
- SRZN $14.38
- COYA $6.50
- Average True Range (ATR)
- SRZN 0.42
- COYA 0.51
- MACD
- SRZN -0.12
- COYA -0.07
- Stochastic Oscillator
- SRZN 5.63
- COYA 3.13
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.